---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-017549"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2023-01-27T23:59:59+00:00"
generated_at: "2026-06-20T07:15:48.974224+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics sells protease inhibitor portfolio to Lighthouse Pharma for up to $150M milestones

## Summary
- Received 7.5% of Lighthouse common stock; eligible for up to $150M in milestone payments.
- Royalties: high single-digit to mid-teens on clinical-stage programs; low single-digit on preclinical.
- Exclusive option to obtain rights to COR388 for animal health until June 30, 2023.
- No salary increases for 2023; executives granted stock options: CEO 600k, others 110k-225k, vesting monthly over 4 years.
- 2022 bonus payouts: CEO $169,287, CAO $137,185, CMO $116,962, CBO $104,650.

## SEC filing metadata
- accession: 0001193125-23-017549
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2023-01-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312523017549/0001193125-23-017549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312523017549/d453314d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-017549
- JSON: https://secwatch.observer/filing/0001193125-23-017549.json
- Plain text: https://secwatch.observer/filing/0001193125-23-017549.txt

## Key facts
- Material Agreements
  Quince Therapeutics, Inc. entered into Asset Purchase Agreement with Lighthouse Pharmaceuticals, Inc. valued at up to $150 million (effective 2023-01-27).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Lighthouse Pharmaceuticals, Inc.
  - Value: up to $150 million
  - Effective: 2023-01-27
  source text: On January 27, 2023, Quince Therapeutics, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Lighthouse Pharmaceuticals, Inc. (“ Purchaser ”) for the sale of its legacy small molecule protease inhibitor portfolio for all uses and indications throughout the world
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523017549/0001193125-23-017549-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.